Unknown

Dataset Information

0

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.


ABSTRACT:

Background

We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).

Methods

A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS).

Results

The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%).

Conclusions

Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.

SUBMITTER: Reardon DA 

PROVIDER: S-EPMC2795431 | BioStudies | 2009-01-01

REPOSITORIES: biostudies

Similar Datasets

2010-01-01 | S-EPMC3018944 | BioStudies
1000-01-01 | S-EPMC2940576 | BioStudies
2011-01-01 | S-EPMC3093337 | BioStudies
2011-01-01 | S-EPMC3158844 | BioStudies
2015-01-01 | S-EPMC4433458 | BioStudies
2008-01-01 | S-EPMC3671765 | BioStudies
2012-01-01 | S-EPMC3616617 | BioStudies
2013-01-01 | S-EPMC3790192 | BioStudies
1000-01-01 | S-EPMC5698580 | BioStudies
2015-01-01 | S-EPMC4492239 | BioStudies